Compare JBDI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JBDI | GDTC |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | Singapore | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.5M |
| IPO Year | 2024 | 2023 |
| Metric | JBDI | GDTC |
|---|---|---|
| Price | $1.04 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 01-01-0001 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,445,000.00 | $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $0.49 | $0.73 |
| 52 Week High | $3.00 | $3.68 |
| Indicator | JBDI | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 68.64 | 53.16 |
| Support Level | $0.52 | $0.80 |
| Resistance Level | $1.35 | $0.90 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 59.63 | 81.79 |
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.